Drug Type Bispecific antibody |
Synonyms Coform and bispecific (Generate) |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), TSLP inhibitors(Thymic stromal lymphopoietin inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Preclinical | United States | 01 Sep 2025 | |
| Severe asthma | Preclinical | United States | 01 Feb 2025 |






